Active substance
Carteolol
- SFDA 3
- US FDA 5
- US price lines 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CARTEOL LP 1% PRLONGED RELEASE EYE DROPS | 10 mg/ml | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 21.25 | Generic · Prescription | CHAUVIN BAUSCH & LOMB | Withdrawn by MAH · Not Marketed |
| CARTEOL LP 2% PRLONGED RELEASE EYE DROPS | 20 mg/ml | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 21.25 | Generic · Prescription | CHAUVIN BAUSCH & LOMB | Withdrawn by MAH · Not Marketed |
| TEOPTIC 2 % EYE DROPS | 20 mg/ml | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 28.75 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CARTEOLOL HYDROCHLORIDE | 1% | solution/drops · ophthalmic | SANDOZ | Prescription | 3 Jan 2000 |
| CARTROL | 2.5MG; 5MG; 10MG | tablet · oral | ABBVIE | Discontinued | 28 Dec 1988 |
| OCUPRESS | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | NOVARTIS | Discontinued | 23 May 1990 |
| CARTEOLOL HYDROCHLORIDE | 1% | solution/drops · ophthalmic | BAUSCH AND LOMB | Discontinued | 20 Jan 2000 |
| CARTEOLOL HYDROCHLORIDE | 1% | solution/drops · ophthalmic | APOTEX INC | Discontinued | 6 Feb 2002 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CARTEOLOL HCL 1% EYE DROPS | $1.62978 | per ML | 23 Sep 2026 |
| US NADAC | CARTEOLOL HCL 1% EYE DROPS | $1.36449 | per ML | 23 Sep 2026 |
| US NADAC | CARTEOLOL HCL 1% EYE DROPS | $1.72987 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.